RxDoctor Payments DataLook up a doctor →

Huma Sohail, MD

Rheumatology · Gainesville, GANPI 1053527275

Payments from drug & device makers

$13,549in general payments, 2019–2025

Across 779 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Novartis$2K
  • Amgen$1K
  • UCB, Inc.$1K
  • Pfizer$861
  • E.r. Squibb & Sons, L.L.C.$830
  • plus $3K from 24 others

What the payments were for

  • Food & beverage$13,43899%
  • Education$1111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,549 in reported general payments places this provider in the 65th percentile of 177 rheumatology providers in Georgia.

See all rheumatology providers in Georgia

Medicare billing

Part B allowed, 2024
$1,224,174
Medicare patients
385
Services billed
65,400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab106$761,753
Enbrel SureclickEtanercept75$600,727
OtezlaApremilast98$523,919
RinvoqUpadacitinib73$478,347
Orencia ClickjectAbatacept79$462,311
Xeljanz XrTofacitinib Citrate50$299,239
Cosentyx Sensoready PenSecukinumab14$169,368
Cosentyx Sensoready (2 Pens)Secukinumab17$155,302
KevzaraSarilumab17$73,412
Cimzia (2 Pack)Certolizumab Pegol11$72,913
Actemra ActpenTocilizumab21$65,896
Hydroxychloroquine Sulfate675$20,995
Leflunomide238$8,432
MethotrexateMethotrexate Sodium412$7,736
Duloxetine Hcl250$5,769

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$1,445$523,91998 claims
AbbVieRinvoq$4,250$478,34773 claims
SanofiKevzara$471$73,41217 claims
UCB, Inc.Cimzia (2 Pack)$1,073$72,91311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 177 rheumatology providers in Georgia.

Other rheumatology in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →